Top 3 Leading Manufacturers Account for Majority of the Revenue of the Radiation-Induced Myelosuppression Treatment Market
The radiation-induced myelosuppression treatment market is dominated by the top 3 manufacturers, i.e., Amgen Inc., Janssen Pharmaceutical NV and Teva Pharmaceutical Industries Ltd., who are competing on the basis of new drug approvals and geographical presence. The manufacturers of radiation-induced myelosuppression treatment are focusing on the expansion of their product portfolios by launching different products in various regions.
Amgen Inc. holds a significant revenue share in the global radiation-induced myelosuppression treatment market. Amgen Inc. also holds patents for various formulations, and is recently facing high competition from the new biosimilars that have been introduced in the radiation-induced myelosuppression treatment market from other manufacturers such as Teva Pharmaceutical Industries Ltd., Janssen Pharmaceutical NV, Sandoz, Pfizer Inc., Mylan NV and others. Through collaborations and partnerships with regional players, the manufacturers of radiation-induced myelosuppression treatment market are focusing on expanding their regional product footprint by launching new and innovative products.
Rapidly Increasing Incidence of Cancer and Decreasing Mortality Rate is Expected to Fuel Growth of the Radiation-Induced Myelosuppression Treatment Market
Although the incidence of cancer is increasing rapidly, the death rate due to cancer has decreased from 1991 to 2015, which is, in turn, contributing to revenue generation in the radiation-induced myelosuppression treatment market. According to SEER Cancer statistics, the overall death rate due to cancer in the U.S. fell by 26.0% during 1991 – 2015, which can be majorly attributed to early diagnosis and the availability of advanced treatment options such as radiotherapy, chemotherapy & surgical procedures. The early diagnosis of cancer has boosted the treatment-seeking rate in developed countries, which is a major driver of the radiation-induced myelosuppression treatment market. The radiation-induced myelosuppression treatment also holds significant potential for revenue generation in developing countries owing to improved healthcare infrastructure.
Request Sample Report @ https://www.futuremarketinsights.com/reports/sample/rep-gb-8116
Patent Expiry of Various Originator Formulations in the Radiation-Induced Myelosuppression Treatment Market
The expiry of the patents of various biologics formulations in the radiation-induced myelosuppression treatment market provides opportunities for other manufacturers in the radiation-induced myelosuppression treatment market to launch biosimilars. Majority of the patents in the radiation-induced myelosuppression treatment market were held by Amgen Inc. However, they have expired in the past five years, i.e. from 2013 to 2018, which has subsequently led to the launch and approval of various biosimilars in the high revenue-generating markets such as North America and Europe. For example, the patent for Amegen Inc.’s Neulasta, a biologic used for the treatment of neutropenia, expired in 2015 in the U.S., following which Sandoz launched Zarxio, the first biosimilar in the U.S. Although the cost variation between originator formulations and biosimilars is only 15% to 20%, it can reduce the economic burden on patients. This is driving the radiation-induced myelosuppression treatment market due to the increasing adoption of biosimilars in radiation-induced myelosuppression treatment.
Improved Efficacy with Iron Therapy along with Erythropoietin-Stimulating Agents is Positively Impacting the Radiation-Induced Myelosuppression Treatment Market
The need for blood transfusion is high in radiation-induced anemia as compared to chemotherapy-induced anemia, due to which erythropoietin-stimulating agents are used alone for radiation-induced myelosuppression treatment. Whereas, the usage of iron therapy along with Erythropoietin-Stimulating Agents (ESA) in radiation-induced myelosuppression treatment significantly lowers the need for blood transfusion. The IV iron therapy coupled with ESA helps bring the RBC count back to the normal level as compared to treatment with ESA alone. As per a study carried out by Auerbach et al., the response rate of ESA alone was 62–73% after being used for 2 to 3 weeks, whereas the response rate for treatment with ESA coupled with iron therapy was 77–86%. This significant change in the response rate will help improve efficacy and therapeutic outcomes as well as patient compliance, thus generating higher revenue in the radiation-induced myelosuppression treatment market.
Request to View TOC @ https://www.futuremarketinsights.com/askus/rep-gb-8116
Competitive Landscape
This section of the report features the profiles of the key players operating in the radiation-induced myelosuppression treatment market based on their market shares, differential strategies, product offerings, marketing approach and company dashboard. Examples of some of the key players featured in this report include Amgen Inc., Janssen Pharmaceutical NV, Teva Pharmaceutical Industries Ltd., Mylan NV, Novartis AG, Pfizer Inc., Janssen Global Services, LLC (Johnson & Johnson), Partner Therapeutics, Inc. and others.
The key manufacturers of radiation-induced myelosuppression treatment are focusing on increasing their geographical footprints as well as launching products to increase their revenue generation in the radiation-induced myelosuppression treatment market.
Definition
Radiation-induced myelosuppression is defined as the decreased ability of the bone marrow to produce blood cells (WBC, RBC and platelets). It occurs most commonly with cancer as an adverse effect of radiation, especially in case of cancers that are located near the bone marrow or near large bones with cavities. Radiation-induced myelosuppression can result in the decreased production of red blood cells (anaemia), white blood cells (leukopenia) and platelets (thrombocytopenia).
No comments:
Post a Comment